Pieris Pharmaceuticals Investor Relations Material
Latest events
Business Combination
Pieris Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Pieris Pharmaceuticals Inc
Access all reports
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company's pipeline includes PRS-080, a multi-receptor antagonist, which is in Phase II clinical trial for the treatment of dry eye disease, and PRS-094, a transmembrane domain protein receptor antagonist for the treatment of melanoma, colorectal cancer, and multiple myeloma. Pieris Pharmaceuticals was founded in 2009 and is based in Lexington, Massachusetts.
Latest articles
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
PIRS
Country
🇺🇸 United States